97 related articles for article (PubMed ID: 20118434)
1. Interferon-induced psychosis as a "psychiatric contraindication" to hepatitis C treatment: a review and case-based discussion.
Silverman BC; Kim AY; Freudenreich O
Psychosomatics; 2010; 51(1):1-7. PubMed ID: 20118434
[TBL] [Abstract][Full Text] [Related]
2. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.
Kumar KS; Russo MW; Borczuk AC; Brown M; Esposito SP; Lobritto SJ; Jacobson IM; Brown RS
Am J Gastroenterol; 2002 Sep; 97(9):2432-40. PubMed ID: 12358269
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of pulmonary toxicity associated with the use of interferon therapy for hepatitis C: case report and review of the literature.
Midturi J; Sierra-Hoffman M; Hurley D; Winn R; Beissner R; Carpenter J
Clin Infect Dis; 2004 Dec; 39(11):1724-9. PubMed ID: 15578378
[TBL] [Abstract][Full Text] [Related]
4. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
[TBL] [Abstract][Full Text] [Related]
5. Treatment of interferon-induced psychosis in patients with comorbid hepatitis C and HIV.
Hoffman RG; Cohen MA; Alfonso CA; Weiss JJ; Jones S; Keller M; Condemarín JR; Chiu NM; Jacobson JM
Psychosomatics; 2003; 44(5):417-20. PubMed ID: 12954918
[No Abstract] [Full Text] [Related]
6. [Antiviral therapy of hepatitis C].
Erhardt A; Petry W; Ebel M; Jablonowski H; Heintges T; Häussinger D
Z Gastroenterol; 2000 Mar; 38(3):259-69. PubMed ID: 10768250
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of everolimus in the treatment of autoimmune hepatitis related to anti-hepatitis C virus therapy after liver transplant: three case reports.
Casanovas T; Argudo A; Peña-Cala MC
Transplant Proc; 2011; 43(6):2233-6. PubMed ID: 21839242
[TBL] [Abstract][Full Text] [Related]
8. Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.
Main J
J Hepatol; 1995; 23 Suppl 2():32-5; discussion 35-6. PubMed ID: 8720292
[TBL] [Abstract][Full Text] [Related]
9. Prolonged psychosis associated with interferon therapy in a patient with hepatitis C: case study and literature review.
Cheng YC; Chen CC; Ho AS; Chiu NY
Psychosomatics; 2009; 50(5):538-42. PubMed ID: 19855041
[TBL] [Abstract][Full Text] [Related]
10. Chronic paranoid psychosis and dementia following interferon-alpha treatment of hepatitis C: a case report.
Drozdz W; Borkowska A; Wilkosc M; Halota W; Dybowska D; Rybakowski JK
Pharmacopsychiatry; 2007 Jul; 40(4):146-8. PubMed ID: 17694476
[TBL] [Abstract][Full Text] [Related]
11. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C.
Schäfer M; Boetsch T; Laakmann G
Addiction; 2000 Jul; 95(7):1101-4. PubMed ID: 10962774
[TBL] [Abstract][Full Text] [Related]
12. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection.
Sidhu-Malik NK; Kaplan AL
J Drugs Dermatol; 2003 Oct; 2(5):570-3. PubMed ID: 14558408
[TBL] [Abstract][Full Text] [Related]
13. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
[TBL] [Abstract][Full Text] [Related]
14. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
[TBL] [Abstract][Full Text] [Related]
15. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C.
Chemello L; Cavalletto L; Bernardinello E; Guido M; Pontisso P; Alberti A
J Hepatol; 1995; 23 Suppl 2():8-12. PubMed ID: 8720287
[TBL] [Abstract][Full Text] [Related]
16. Psychiatric comorbidity does not predict interferon treatment completion rates in hepatitis C seropositive veterans.
Dollarhide AW; Loh C; Leckband SG; Endow-Eyer R; Robinson S; Meyer JM
J Clin Gastroenterol; 2007 Mar; 41(3):322-8. PubMed ID: 17426475
[TBL] [Abstract][Full Text] [Related]
17. [Cotton-wool spots appearing during the course of treatment with interferon and ribavirin].
Avérous K; Rocher P; Bonsch M; Le Corguillé M; Eugène C
Gastroenterol Clin Biol; 2003 Oct; 27(10):945-6. PubMed ID: 14631312
[No Abstract] [Full Text] [Related]
18. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.
Bizollon T; Palazzo U; Ducerf C; Chevallier M; Elliott M; Baulieux J; Pouyet M; Trepo C
Hepatology; 1997 Aug; 26(2):500-4. PubMed ID: 9252166
[TBL] [Abstract][Full Text] [Related]
19. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
[TBL] [Abstract][Full Text] [Related]
20. Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death.
Costiniuk CT; Camacho F; Cooper CL
Clin Infect Dis; 2008 Jul; 47(2):198-202. PubMed ID: 18532889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
